Research
The trials behind tirzepatide
Our guide to compounded medication explains why findings for one product cannot establish what is in a seller’s vial. The trials below studied approved or investigational products.
Every trial below was located on PubMed and its PMID resolved before anything here was written. Each figure is reported with the comparator it was measured against, the number of weeks it took, and the number of participants it came from.
- Trials charted below
- 4
- Participants in charted trials
- 5,839
- Longest charted trial, weeks
- 88
Trials with comparable weight outcomes
- SURMOUNT-1
20.9%of body weight lost at the top dose, against 3.1% on placebo
At week 72 mean weight change was -15.0% on 5 mg, -19.5% on 10 mg and -20.9% on 15 mg, against -3.1% on placebo. In the 15 mg group 57% of participants lost 20% of body weight or more, against 3% on placebo.
- Participants
- 2,539
- Weeks
- 72
- Against
- Placebo
Jastreboff AM, New England Journal of Medicine 2022 · PMID 35658024
- SURPASS-2
2.30percentage points off HbA1c, against 1.86 on semaglutide
Glycated hemoglobin fell by 2.01, 2.24 and 2.30 percentage points on tirzepatide 5 mg, 10 mg and 15 mg, against 1.86 points on semaglutide 1 mg. Tirzepatide was noninferior and superior at every dose. Weight fell further on tirzepatide, by an estimated 1.9 kg, 3.6 kg and 5.5 kg respectively.
- Participants
- 1,879
- Weeks
- 40
- Against
- Semaglutide 1 mg once weekly
Frías JP, New England Journal of Medicine 2021 · PMID 34170647
- SURMOUNT-4
14.0%regained by those switched to placebo, against 5.5% lost on tirzepatide
Between week 36 and week 88 weight changed by -5.5% on continued tirzepatide and by +14.0% on placebo, a difference of 19.4 percentage points. Participants had lost a mean 20.9% during the lead-in; 89.5% of those continuing held at least 80% of that loss, against 16.6% of those switched to placebo.
- Participants
- 670
- Weeks
- 88
- Against
- Placebo, by withdrawal of tirzepatide
Aronne LJ, JAMA 2024 · PMID 38078870
- SURMOUNT-5
20.2%of body weight lost, against 13.7% on semaglutide
At week 72 weight fell by 20.2% on tirzepatide and 13.7% on semaglutide. Waist circumference fell by 18.4 cm and 13.0 cm respectively.
- Participants
- 751
- Weeks
- 72
- Against
- Semaglutide at 1.7 mg or 2.4 mg once weekly
Aronne LJ, New England Journal of Medicine 2025 · PMID 40353578
More from the research
- Does tirzepatide cause cancer? The rat data and the human dataWhat 13 tirzepatide trials found about cancer, why the thyroid warning exists, and what the trial follow-up cannot rule out.
- Tirzepatide and diabetes prevention: three-year evidenceWhat the 176-week SURMOUNT-1 follow-up found in obesity and prediabetes, including the limits of prevention claims and off-treatment results.
- Tirzepatide price evidence: November 2026An original analysis of 384 compounded tirzepatide providers: comparable monthly prices, advertised-only quotes and evidence age, with downloadable data.
- SUMMIT: tirzepatide and heart failureWhat SUMMIT studied in obesity-related HFpEF, how clinical events differ from symptom scores, and the limits of applying results to compounded products.
- SURMOUNT-2: tirzepatide in type 2 diabetesHow SURMOUNT-2 studied weight management in people with type 2 diabetes, and why its results should not be mixed with trials excluding diabetes.
- SURMOUNT-3: tirzepatide after lifestyle treatmentUnderstand the SURMOUNT-3 lifestyle lead-in, additional weight loss after randomization, and why the results are not an individual forecast.
- SURMOUNT-OSA: tirzepatide sleep-apnea trialsHow the two SURMOUNT-OSA trials separated PAP users from nonusers, what AHI measures, and why treatment changes require clinical review.
- SURPASS-4: interpreting tirzepatide kidney findingsWhat the post hoc SURPASS-4 kidney analysis compared, how eGFR and albuminuria differ, and why the result needs careful interpretation.
- SYNERGY-NASH: tirzepatide and liver fibrosisUnderstand the phase 2 tirzepatide MASH trial, biopsy-based outcomes, fibrosis terminology, and what the findings do not prove.
- Tirzepatide weight loss results, week by weekWhat SURMOUNT-1, Study 1 in the Zepbound label, found at weeks 8, 12, 24 and 72: most of the weight came off in the first six months, then the loss slowed.
What they measured
3 of the 4 charted trials report weight change per study arm. Each chart below draws only figures that appear in that trial’s own published abstract, beside the comparator it was measured against — which is the part most coverage drops.
Filled bars are tirzepatide; the outlined bar is placebo. Read from the published abstract, PMID 35658024.
Filled bar is tirzepatide; the outlined bar is placebo, by withdrawal of tirzepatide. Read from the published abstract, PMID 38078870.
Filled bar is tirzepatide; the outlined bar is semaglutide at 1.7 mg or 2.4 mg once weekly. Read from the published abstract, PMID 40353578.
The charted trials at a glance
| Trial | Compared against | Participants | Weeks |
|---|---|---|---|
| SURMOUNT-1 | Placebo | 2,539 | 72 |
| SURPASS-2 | Semaglutide 1 mg once weekly | 1,879 | 40 |
| SURMOUNT-4 | Placebo, by withdrawal of tirzepatide | 670 | 88 |
| SURMOUNT-5 | Semaglutide at 1.7 mg or 2.4 mg once weekly | 751 | 72 |
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. PMID: 35658024. NCT04184622.
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515. PMID: 34170647. NCT03987919.
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870. NCT04660643.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025;393(1):26-36. PMID: 40353578. NCT05822830.